Despite the significance of IVT in stroke care, the initial 24 h following the administration of intravenous recombinant tissue-type plasminogen activator (tPA) exhibit a diverse clinical course, with a majority of patients showing improvement, some maintaining a stable condition, and approximately 10% undergoing early neurological deterioration (END) [6]. The gene discussed is PLAT; the disease is stroke disorder.